GGrantIndex
Sort

50,496 grants matching lung cancer

BCG overexpressing a small molecule STING agonist as a vaccine for TB

$991,112
Todd Wallach · Oncosting Llc · R44 · FY2025 · AI

2/3: The Chicago Cancer Health Equity Collaborative (ChicagoCHEC)

$991,093
Christina Ciecierski · Northeastern Illinois University · U54 · FY2020 · CA

Lung cancer in East Africa and the relationship to HIV-1 infection: epidemiology, molecular characterization and imaging

$990,912
Robert A Salata · Case Western Reserve University · U54 · FY2021 · CA

Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA

$990,771
Michael T Barrett · Binary Genomics, Inc. · R44 · FY2024 · CA

Development of novel therapeutics for cancer cachexia

$990,411
Scott Matthew Ebert · Emmyon, Inc. · R44 · FY2023 · CA

Preclinical Development of Therapeutics in Murine Models of Lung Cancer

$990,320
Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Probing functioning lung at the cellular resolution in health and disease

$990,000
Hadi Tavakoli Nia · Boston University (Charles River Campus) · DP2 · FY2025 · HL

Reducing Cancer Health Disparities in Detroit

$989,994
Ann G Schwartz · Wayne State University · P20 · FY2022 · CA

Mass Spectrometry Quantitation

$989,919
Leesa Deterding · National Institute Of Environmental Health Sciences · ZIC · FY2021 · ES

A Phase II Trial of ACAPHA in Former Smokers with IEN.

$989,903
British Columbia Cancer Agency · U01 · FY2004 · CA

Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer

$989,826
Eliseu O. De Oliveira · Coare Holdings, Inc. · R44 · FY2021 · CA

Genetic Toxicity Testing Services for the NTP

$989,488
Les Recio · Integrated Laboratory Systems, Llc · N01 · FY2018 · ES

CardioWatch: An Omics-Based Prediction Assay for Cardiac Late Effects ofAcute Radiation

$989,322
Tomas Kanholm · Nelson Scientific Labs Llc · R44 · FY2024 · AI

Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency

$989,251
Alan S. Wayne · Children'S Hospital Of Los Angeles · U01 · FY2023 · AI

The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis

$989,186
Chetan Seshadri · University Of Washington · R01 · FY2025 · AI

Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer

$988,765
Zdravka O. Medarova · Transcode Therapeutics, Inc. · R44 · FY2025 · CA

Pharmacogenetic Studies

$988,591
Neil E. Caporaso · Division Of Cancer Epidemiology And Genetics · ZIA · FY2010 · CA

ACQUISITION OF THE INVEON SMALL ANIMAL PET/CT SYSTEM

$988,523
Richard Andre Laforest · Washington University · S10 · FY2009 · RR

Optimizing Implementation in Cancer Control: OPTICC

$988,432
Bryan J. Weiner · University Of Washington · P50 · FY2019 · CA

Risk prediction methods

$988,223
Mitchell H Gail · Division Of Cancer Epidemiology And Genetics · ZIA · FY2010 · CA

PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.

$988,207
Greg Bertenshaw · Biomarker Strategies, Llc · R44 · FY2017 · CA

Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

$988,000
Ke Zhang · Pacdna Llc · R42 · FY2024 · CA

Red Cell Biology

$987,510
David M. Bodine · National Human Genome Research Institute · ZIA · FY2019 · HG

Northwestern Cancer Prevention Consortium

$987,500
Seema Ahsan Khan · Northwestern University At Chicago · UG1 · FY2019 · CA

DIESEL PARTICLE EXPOSURE AND LUNG CANCER

$987,450
Brigham And Women'S Hospital · R01 · FY2002 · CA